UBE1L causes lung cancer growth suppression by targeting cyclin D1

Molecular Cancer Therapeutics

Volumn 7, Issue 12, 2008, Pages 3780-3788

  Feng, Qing ^a,d   Sekula, David ^a   Guo, Yongli ^a   Liu, Xi ^a   Black, Candice C ^a   Galimberti, Fabrizio ^a   Shah, Sumit J ^a   Sempere, Lorenzo F ^a   Memoli, Vincent ^a,b   Andersen, Jesper B ^c   Hassel, Bret A ^c   Dragnev, Konstantin ^a,b   Dmitrovsky, Ethan ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BEXAROTENE; CYCLIN D1; CYCLOHEXIMIDE; E1 LIKE UBIQUITIN ACTIVATING ENZYME; KI 67 ANTIGEN; LYSINE; MESSENGER RNA; PROTEIN ISG15; PROTEIN UBP43; PROTEINASE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COMPLEX FORMATION; CONJUGATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY;

ANTICARCINOGENIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLOHEXIMIDE; CYTOKINES; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MODELS, BIOLOGICAL; PLASMIDS; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITINS;

EID: 57749092178     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0753     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Langenfeld J, Lonardo F, Kiyokawa H, et al. Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation. Oncogene 1996;13:1983-90.
3. Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci U S A 1997;94:12070-4.
4. Lonardo F, Dragnev KH, Freemantle SJ, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002;8:54-60.
5. Boyle JO, Langenfeld J, Lonardo F, et al. Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. J Natl Cancer Inst 1999;91:373-9.
6. 1 cyclins: implications for combination therapy. Clin Cancer Res 2004;10:2570-7.
7. Petty WJ, Dragnev KH, Dmitrovsky E. Cyclin D1 as a target for chemoprevention. Lung Cancer 2003;41 Suppl 1:S155-61.
8. Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ, Dmitrovsky E. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem 1999;274:22013-8.
9. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 1999;59:2470-6.
10. Ma Y, Fiering S, Black C, et al. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A 2007;104:4089-94.
11. Petty WJ, Dragnev KH, Memoli VA, et al. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 2004;10:7547-54.
12. Dragnev KH, Petty WJ, Shah SJ, et al. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res 2007;13:1794-800.
13. Dragnev KH, Petty WJ, Shah S, et al. Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 2005;23:8757-64.
14. Kitareewan S, Pitha-Rowe I, Sekula D, et al. UBE1L is a retinoid target that triggers PML/RARα degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2002;99:3806-11.
15. Pitha-Rowe I, Hassel BA, Dmitrovsky E. Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. J Biol Chem 2004;279:18178-87.
16. Pitha-Rowe I, Petty WJ, Feng Q, et al. Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res 2004;64:8109-15.
17. Kok K, Hofstra R, Pilz A, et al. A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme. Proc Natl Acad Sci U S A 1993;90:6071-5.
18. Kok K, Van den Berg A, Veldhuis PM, Franke M, Terpstra P, Buys CH. The genomic structure of the human UBE1L gene. Gene Expr 1995;4:163-75.
19. McLaughlin PM, Helfrich W, Kok K, et al. The ubiquitin-activating enzyme E1-like protein in lung cancer cell lines. Int J Cancer 2000;85:871-6.
20. Liu X, Sempere L, Galimberti F, et al. Uncovering growth suppressive microRNAs in lung cancer. Clin Cancer Res. In press.
21. Liu M, Li X-L, Hassel BA. Proteasomes modulate conjugation to the ubiquitin-like protein, ISG15. J Biol Chem 2003;278:1594-602.
22. Shah SJ, Blumen S, Pitha-Rowe I, et al. UBE1L represses PML/RARα by targeting the PML domain for ISG15ylation. Mol Cancer Ther 2008;7:905-14.
23. Feng Q, Sekula D, Müller R, Freemantle SJ, Dmitrovsky E. Uncovering residues that regulate cyclin D1 proteasomal degradation. Oncogene 2007;26:5098-106.
24. Ma Y, Feng Q, Sekula D, Diehl JA, Freemantle SJ, Dmitrovsky E. Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res 2005;65:6476-83.
25. Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF. Stage-associated over expression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer 2006;94:1465-71.
26. Kim KI, Zhang DE. UBP43, an ISG15-specific deconjugating enzyme: expression, purification, and enzymatic assays. Methods Enzymol 2005;398:491-9.
27. Zhao C, Beaudenon SL, Kelley ML, et al. The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-α/β-induced ubiquitin-like protein. Proc Natl Acad Sci U S A 2004;101:7578-82.
28. Li XL, Blackford JA, Judge CS, et al. RNase-L-dependent destabilization of interferon-induced mRNAs. A role for the 2-5A system in attenuation of the interferon response. J Biol Chem 2000;275:8880-8.
29. Freemantle SJ, Liu X, Feng Q, et al. Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem 2007;102:869-77.
30. Yan M, Luo JK, Ritchie KJ, et al. Ubp43 regulates BCR-ABL leukemogenesis via the type I interferon receptor signaling. Blood 2007;110:305-12.
31. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic intervention. Mol Cancer 2007;6:24.
32. Dmitrovsky E, Sporn MB. Pharmacology of cancer chemoprevention. In: Bertino J, editor. Encyclopedia of cancer. 2nd ed. St. Louis: Academic Press; 2002. p. 449-55.